Lu AA21004 for the treatment of mood and anxiety disorders enters
into clinical phase III
The clinical phase III program will consist of several clinical
studies that will be conducted at investigational sites around the
world. More than 2,000 patients are expected to be enrolled in the
clinical phase III program.
Lu AA21004, discovered by Lundbeck and being jointly developed by
Lundbeck and Takeda, belongs to a new chemical class having a mode of
action that is different from currently marketed antidepressants. In
the clinical phase II study, Lu AA21004 showed highly significant
improvements on the primary efficacy endpoints for both 5 and 10 mg
doses compared to placebo and had an attractive safety profile."Lu AA21004 is the most advanced project in our portfolio of new and
innovative compounds for the treatment of mood and anxiety disorders,
all of which have the potential to treat unmet patient needs", said
Senior Vice President Anders Gersel Pedersen, head of Development at
Lundbeck. "Our collaboration with Takeda is working very well and we
look forward to advancing the development of Lu AA21004 with Takeda."
Lundbeck and Takeda formed an alliance in September 2007 to develop
and commercialize a portfolio of novel compounds in the US and Japan
for the treatment of mood and anxiety disorders, including Lu AA21004
and Lu AA24530, which is in clinical phase II development."We are pleased with the continued positive results from the Lu
AA21004 development program which is under collaboration with
Lundbeck," said Dr. Masaomi Miyamoto, General Manager of the
Pharmaceutical Development Division of Takeda. "Advancing this
compound for the treatment of mood and anxiety disorders to Phase III
represents a significant achievement in Takeda's enhancement of our
R&D pipeline in the central nervous system field."
Lundbeck will receive a milestone payment from Takeda of USD 40
million in connection with the advancement of Lu AA21004 into
clinical phase III. The payment will be booked by Lundbeck as other
revenue in the fourth quarter of 2007.
Excluding non-recurring items like the payment from Takeda the
content of this release will have no influence on the Lundbeck
Group's financial forecast for 2007.
Takeda contact
Investors & Media:
Seizo Masuda
Coordinator, Corporate Communications Dept.
+81-3-3278-2037
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79 +45 36 43 20 81
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
________________________
Stock Exchange Release No 314 - 18 December 2007
About Takeda
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global
company with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to striving toward better health for
individuals and progress in medicine by developing superior
pharmaceutical products. Additional information about Takeda is
available through its corporate website, www.takeda.com.
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
